# A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

> **NCT01525017** · PHASE1 · COMPLETED · sponsor: **Mendus** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Combig-DC (allogeneic dendritic cells) Cancer Vaccine

## Key facts

- **NCT ID:** NCT01525017
- **Lead sponsor:** Mendus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01525017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01525017, "A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01525017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*